Center for Global Health R&D Policy Assessment

Follow us on:

Close
warning: Missing argument 3 for views_plugin_query_default::init(), called in /var/aegir/ghrdpac-2011-02-28T19-34-30/profiles/accra/modules/custom/searchlight/views/searchlight_plugin_query_v3.inc on line 21 and defined in /var/aegir/ghrdpac-2011-02-28T19-34-30/profiles/accra/modules/contrib/views/plugins/views_plugin_query_default.inc on line 80.

TB Vaccine Investment Partnership

The Aeras Global TB Vaccine Foundation is nearing late-stage clinical trials for several of its candidate vaccines. There is a potential market in both developed and developing countries for new TB vaccines, with the total developed country market estimated to be $300 million a year. One way of encouraging private investment is to create a new investor-owned for-profit company (NewCo) to hold technologies needed for developing and commercializing TB vaccines as they approach Phase IIB trials. Investors would include technology owners, Aeras and private equity investors. Aeras could manage the virtual company under a service contract and technology owners would have the ability to buy out other partners.

Sources: 

Singh, K.J. “Leveraging Private Financing For Late-Stage Product Research and Development.” Presentation, Global Health Inaugural Meeting of the Innovative Financing Advisory Group from Brookings Institution, August 2, 2007. Available here.